Mor Research Applications
Met Mor’s team at Mixiii 2024, March 5-6, Jerusalem
Companies, entrepreneurs and investors please contact: sari@mor-research.com
NGS Solutions
NGS’ Healthy Heights Available at Walmart
Walmart now stocking Healthy Heights with significant opportunities for expansion
IIA invests 25M NIS in innovation center in Be’er Sheva
Synergy 7 jointly owned by Mor, Ben Gurion U, B.G. Negev, Soroka , Elbit , Incubit Technological Entrepreneurship and Merage
Exero Medical
Exero’s Pivotal Clinical Study Approved by WCG
Exero’s multi-center study expected to commence during Q1 2024.
Can-Fite
CAN-FITE expands license deal with Ewopharma
Exclusive distribution agreement for psoriasis and hepatocellular carcinoma (HCC) and nonalcoholic steatohepatitis (NASH).
Mediwound
Mediwound announces positive data from clinical study
Phase I/II study evaluated safety and efficacy of MW005 for low-risk Basal Cell Carcinoma (BCC).
Cathworks
Cathworks announces first patient in clinical trial
Evaluates the clinical benefits of FFRangio® System in coronary artery disease (CAD)
Nanox
Nanox.AI New Global Partnership with Ferrum Health
Partnership on AI platform – Bone solution (HealthOST) and cardiac solution (HealthCCSng)
Exero
Unorthodox Ventures Invests in Exero Medical
Unorthodox and Founder Carey Smith provide bridge financing toward a series A round
DiA
DiA Secures FDA Clearance for its New AI Software
LVivo IQS for cardiac ultrasound users with real-time image quality feedback while scanning
